Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 7/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | VEGFA | P15692 | 2/20 | 0.43 |
| ▸ | FLT1 | P17948 | 2/20 | 0.43 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1509716 | 0.92 | EGLN1 (0.53) | EGLN1POLBMAPTGAASMN1; SMN2 | |
| SCHEMBL1509146 | 0.89 | EGLN1 (0.49) | EGLN1MAPTGAATSHRMEN1 | |
| SCHEMBL966853 | 0.88 | KMT2A (0.53) | EGLN1POLBMAPTGAASMN1; SMN2 | |
| SCHEMBL8882701 | 0.86 | MEN1 (0.50) | EGLN1POLBMAPTGAASMN1; SMN2 | |
| SCHEMBL8880594 | 0.86 | MEN1 (0.50) | EGLN1POLBMAPTGAASMN1; SMN2 | |
| SCHEMBL8881979 | 0.86 | MEN1 (0.50) | EGLN1POLBMAPTGAASMN1; SMN2 | |
| SCHEMBL8883714 | 0.86 | MEN1 (0.50) | EGLN1POLBMAPTGAASMN1; SMN2 | |
| SCHEMBL14735807 | 0.86 | MAPT (0.43) | EGLN1POLBMAPTGAASMN1; SMN2 | |
| SCHEMBL20336258 | 0.84 | GAA (0.51) | EGLN1POLBMAPTGAASMN1; SMN2 | |
| SCHEMBL14735698 | 0.80 | MAPT (0.46) | EGLN1POLBMAPTGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150080425-A1 | METHODS FOR TREATING ANEMIA IN SUBJECTS HAVING KIDNEY FAILURE USING INHIBITORS OF HYPOXIA-INDUCIBLE FACTOR (HIF) HYDROXYLASE | FIBROGEN, INC. (US) | 2015-03-19 | — | — | US | claimed |
| EP-1463823-B1 | METHODS OF INCREASING ENDOGENOUS ERYTHROPOIETIN (EPO) | FIBROGEN INC (US) | 2013-03-06 | — | — | EP | claimed |
| EP-2298301-B2 | MEDICAMENTS FOR TREATING ANEMIA ASSOCIATED WITH KIDNEY DISEASE | FIBROGEN INC (US) | 2022-11-16 | — | — | EP | disclosed |
| US-20210369702-A1 | METHODS FOR TREATING ANEMIA IN SUBJECTS HAVING KIDNEY FAILURE USING INHIBITORS OF HYPOXIA-INDUCIBLE FACTOR (HIF) HYDROXYLASE | FIBROGEN, INC. (US) | 2021-12-02 | — | — | US | disclosed |
| EP-3520784-A1 | HIF PROLYL HYDROXYLASE INHIBITOR FOR TREATMENT OF ANEMIA | Fibrogen, Inc. (US) | 2019-08-07 | — | — | EP | disclosed |
| EP-2324834-B1 | Methods of Increasing Endogenous Erythropoietin (EPO) | FIBROGEN INC (US) | 2019-05-08 | — | — | EP | disclosed |
| EP-2289531-B1 | Medicaments for the treatment or prevention of anemia | FIBROGEN INC (US) | 2018-07-04 | — | — | EP | disclosed |
| EP-2298301-B1 | MEDICAMENTS FOR TREATING ANEMIA ASSOCIATED WITH KIDNEY DISEASE | FIBROGEN INC (US) | 2018-07-04 | — | — | EP | disclosed |
| US-20170312268-A1 | METHODS FOR TREATING A NEUROLOGICAL DISORDER IN A SUBJECT USING INHIBITORS OF HYPOXIA-INDUCIBLE FACTOR (HIF) PROYL HYDROXYLASE | FIBROGEN, INC. (US) | 2017-11-02 | — | — | US | disclosed |
| US-20150080425-A1 | METHODS FOR TREATING ANEMIA IN SUBJECTS HAVING KIDNEY FAILURE USING INHIBITORS OF HYPOXIA-INDUCIBLE FACTOR (HIF) HYDROXYLASE | FIBROGEN, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| US-20130203805-A1 | Methods for treating anemia using inhibitors of hypoxia-inducible factor (HIF) hydroxylase | FIBROGEN, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| EP-2298301-A2 | Medicaments for increasing endogenous Erythropoietin (EPO) | Fibrogen, Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| EP-2289531-A2 | Medicaments for increasing endogenous erythropoietine (EPO) | FIBROGEN, INC. (US) | 2011-03-02 | — | — | EP | disclosed |
| US-20060183695-A1 | Methods of increasing endogenous erythropoietin (EPO) | FIBROGEN, INC. (US) | 2006-08-17 | — | — | US | disclosed |
| US-20060178317-A1 | Methods of increasing endogenous erythropoietin (EPO) | FIBROGEN, INC. (US) | 2006-08-10 | — | — | US | disclosed |
| US-20060178316-A1 | Methods of increasing endogenous erythropoietin (EPO) | FIBROGEN, INC. (US) | 2006-08-10 | — | — | US | disclosed |
| EP-1463823-A4 | METHODS OF INCREASING ENDOGENOUS ERYTHROPOIETIN (EPO) | FIBROGEN INC (US) | 2005-11-16 | — | — | EP | disclosed |
| EP-1463823-A2 | METHODS OF INCREASING ENDOGENOUS ERYTHROPOIETIN (EPO) | FIBROGEN, INC. (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20030153503-A1 | Methods of increasing endogenous erythropoietin (EPO) | FIBROGEN, INC. | 2003-08-14 | — | — | US | disclosed |
| WO-2003053997-A2 | METHODS OF INCREASING ENDOGENOUS ERYTHROPOIETIN (EPO) | FIBROGEN, INC. (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080425-A1 | METHODS FOR TREATING ANEMIA IN SUBJECTS HAVING KIDNEY FAILURE USING INHIBITORS OF HYPOXIA-INDUCIBLE FACTOR (HIF) HYDROXYLASE | HIF1AN, HIF1A, EGLN2 | EGLN1 5/4885POLB 2542/4885MAPT 4792/4885 |
| US-20060178317-A1 | Methods of increasing endogenous erythropoietin (EPO) | EPOR, EGLN3, EGLN2 | EGLN1 13/4885POLB 1907/4885MAPT 4673/4885 |
| US-20210369702-A1 | METHODS FOR TREATING ANEMIA IN SUBJECTS HAVING KIDNEY FAILURE USING INHIBITORS OF HYPOXIA-INDUCIBLE FACTOR (HIF) HYDROXYLASE | HIF1AN, HIF1A, EGLN2 | EGLN1 5/4885POLB 2542/4885MAPT 4792/4885 |
| US-20060183695-A1 | Methods of increasing endogenous erythropoietin (EPO) | EPOR, EGLN3, EGLN2 | EGLN1 13/4885POLB 1907/4885MAPT 4673/4885 |
| US-20170312268-A1 | METHODS FOR TREATING A NEUROLOGICAL DISORDER IN A SUBJECT USING INHIBITORS OF HYPOXIA-INDUCIBLE FACTOR (HIF) PROYL HYDROXYLASE | HIF1AN, EGLN2, EGLN3 | EGLN1 9/4885POLB 2480/4885MAPT 974/4885 |
| US-20030153503-A1 | Methods of increasing endogenous erythropoietin (EPO) | EPOR, EGLN3, EGLN2 | EGLN1 13/4885POLB 1907/4885MAPT 4673/4885 |
| US-20130203805-A1 | Methods for treating anemia using inhibitors of hypoxia-inducible factor (HIF) hydroxylase | HIF1AN, HIF1A, EGLN2 | EGLN1 6/4885POLB 1781/4885MAPT 4834/4885 |
| US-20060178316-A1 | Methods of increasing endogenous erythropoietin (EPO) | EPOR, EGLN3, EGLN2 | EGLN1 13/4885POLB 1907/4885MAPT 4673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.